NCT04639388 Understanding of Psychotic Disorders in Children With 22q11.2DS
| NCT ID | NCT04639388 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hôpital le Vinatier |
| Condition | 22q11.2 Deletion Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2020-11-13 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2020-11-13 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study PremiCeS22 will investigate the prodromal signals at the onset of psychotic disorders of children with 22q11.2 deletion syndrome
Eligibility Criteria
Inclusion Criteria: * Diagnosis of 22q11.2 deletion syndrome or no developmental disease * Aged from 4 to 13 years old * French language Exclusion Criteria: * Diagnosis of intellectual deficiency according to DSM 5 criteria * Drug prescribed for somatic condition that could influence cerebral functioning
Contact & Investigator
Marie-Noëlle BABINET
PRINCIPAL INVESTIGATOR
CH LE VINATIER
Frequently Asked Questions
Who can join the NCT04639388 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, up to 13 Years, studying 22q11.2 Deletion Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04639388 currently recruiting?
Yes, NCT04639388 is actively recruiting participants. Contact the research team at caroline.demily@ch-le-vinatier.fr for enrollment information.
Where is the NCT04639388 trial being conducted?
This trial is being conducted at Lyon, France.
Who is sponsoring the NCT04639388 clinical trial?
NCT04639388 is sponsored by Hôpital le Vinatier. The principal investigator is Marie-Noëlle BABINET at CH LE VINATIER. The trial plans to enroll 80 participants.